Synthomer Plc · LSE:SYNT

Synthomer — FY2014 Earnings Presentation

25 slides from Synthomer's earnings presentation, Feb 26, 2015

  1. Slide 1: 2014 Preliminary Results

    2014 Preliminary Results 26th February 2015

  2. Slide 2: Introduction – Calum MacLean

    Introduction – Calum MacLean 2  Calum MacLean, appointed Chief Executive Officer, January 2015 • Senior Board executive and a founding member of INEOS • Executive Chairman of INEOS Olefins and Polymers Europe • Chairman of Styrolution, INEOS’s joint venture with BASF, and Petroineos Refining, INEOS

  3. Slide 3: Highlights

    Highlights 3  Robust performance in the context of a challenging macro‐economic environment  Positive H1 in Europe offset by impact of weaker H2 demand • Year‐on‐year improvement in unit margins  Asia and ROW weak but encouraging H2 trends • Nitrile volumes up towards the year end • Margins conti

  4. Slide 4: Financial Review

    4 FINANCIAL REVIEW David Blackwood – Chief Financial Officer

  5. Slide 5: FY Results: Financial Highlights

    FY Results: Financial Highlights 5 % Change 2014 FY 2013 FY As reported Constant FX Revenue (1) (£m) 990.5 1,054.9 (6.1)% (2.0)% EBIT (1) (£m) 96.5 104.8 (7.9)% (3.4)% PBT (1) (£m) 86.0 90.1 (4.6)% (0.2)% EPS 19.5p 20.7p (5.8)% DPS (ordinary) 7.8p 6.0p 30.0% Net debt (£m) 112.1 133.6 (1) Underlying

  6. Slide 6: Europe & North America

    Europe & North America (69% Sales, 83% EBIT) 6 % Change 2014 FY 2013 FY As reported Constant FX Sales (£m) 687.2 744.8 (7.7)% (5.7)% EBIT (£m) 85.7 89.8 (4.6)% (0.7)% Volumes (Ktes) 794.3 805.5 (1.4)%  EBIT down – £4.1 million (of which £3.4 million translation)  Volumes down 24.4 ktes • Exited lo

  7. Slide 7: Asia & ROW

    Asia & ROW (31% Sales, 17% EBIT) 7 % Change 2014 FY 2013 FY As reported Constant FX Sales (£m) 303.3 310.1 (2.2)% 7.1% EBIT (£m) 17.8 23.1 (22.9)% (17.5)% Volumes (Ktes) 396.5 376.2 5.4 %  EBIT down – £5.3 million (of which £1.3 million translation)  Nitrile continued to improve after weak H1 • Vo

  8. Slide 8: Free Cash Flow

    Free Cash Flow 8 2014 2013 Underlying operating profit (£m) – exc. JV 91.2 99.9 Depreciation (£m) 21.5 19.2 Movement in working capital (£m) (9.1) 5.8 Capital expenditure (net) (£m) (1) (21.5) (35.0) Tax, interest, pensions (£m) (2) (30.9) (31.6) Free cash flow (£m) 51.2 58.3 (1) 2014 £22.0m gross;

  9. Slide 9: Net Cash Flow

    Net Cash Flow 9 2014 2013 Free cash flow (£m) 51.2 58.3 Restructuring (£m) (3.8) (3.8) Purchase of business (£m) (8.6) ‐ Dividends paid (£m) (22.4) (19.4) Exchange / other (£m) (1) 5.1 (12.9) Movement in borrowings (£m) 21.5 22.2 Closing net debt (£m) 112.1 133.6 (1) Includes settlement of LTIP ince

  10. Slide 10: Further Progress on Malaysian Land Sales

    Further Progress on Malaysian Land Sales 10  Additional land sales contract signed January 2015  Current position on contracted sales – gross proceeds MYR 232.8 million  Group share from 70% owned subsidiary – MYR 154.8 million – approx. £28 million  Cash expected end 2015 – some risk this could

  11. Slide 11: Capital Structure / Net Debt

    Capital Structure / Net Debt 11 2014 2013 Net Cash (£m) 24.9 64.8 Term Debt (£m) (137.0) (198.4) Net Debt (£m) (112.1) (133.6) Undrawn committed facilities (£m) 85.3 60.0 Net Debt: EBITDA (LTM) <1.0 1.1  Conservative balance sheet – net debt: EBITDA below 1 times  Substantial available liquidity 

  12. Slide 12: Full Year Dividend / Capital Management

    Full Year Dividend / Capital Management 12  Full year ordinary dividend of 7.8p  In line with announcement at interim results on dividend policy  Cover of 2.5x  Special dividend of 7.8p per share  First ever special dividend, in line with capital management policy  Represents a pay‐out of £26.

  13. Slide 13: Business Review

    13 BUSINESS REVIEW Calum MacLean – Chief Executive Officer

  14. Slide 14: 2014 Operating Review – Europe and North America

    14 2014 Operating Review – Europe and North America  EBIT down £4.1 million; £0.7 million (0.7%) lower on a constant currency basis • Impacted by H2 demand weakness, after a better H1  Volume declines mainly due to exit of 18 ktes of low margin compounds • Underlying volume improvements in H1 offs

  15. Slide 15: 2014 Operating Review – Europe and North America

    2014 Operating Review – Europe and North America 15  Cost saving programme on track – “Synthomer 2015” • Annual benefits over €10 million run rate by end 2015 • Cost €10 million revenue; €5 million capex  New product pipeline continues to contribute  Completed investment in bio‐polymer hybrid lat

  16. Slide 16: 2014 Operating Review – Asia and ROW

    16 2014 Operating Review – Asia and ROW  EBIT down £5.3 million; £4.0 million (17%) lower on a constant currency basis  Nitrile improved in H2 • Demand improved towards end 2014 • Margins improved through H2 • Major new product launches – which will deliver up to 50 ktes extra capacity  Non‐nitri

  17. Slide 17: 2014 Operating Review – Asia and Rest Of World

    2014 Operating Review – Asia and Rest Of World 17  Middle East 28 ktes capacity commissioned • Saudi plant now a 100 kte plant  Two major new nitrile products launches in H2 • Will create up to 50 ktes of extra nitrile capacity  Land sales to date now worth approx. £28 million to Group • Proceeds

  18. Slide 18: Crude and Downstream Raw Materials

    Crude and Downstream Raw Materials 18  Monomer prices have fallen across the board  Combination of lower oil and supply demand for these monomers  Generally passed through to customers with a circa one month lag  Some cash margin improvement possible in low volume specialty products – but modest

  19. Slide 19: Innovation

    19 Innovation  New product contribution continues to improve • 16% of current sales from products launched in last 5 years o Was 12% in 2013 • On track for mid‐term target of 20% of revenues  Recent launches have had a material impact on business performance • 2 new nitrile grades for glove dippin

  20. Slide 20: Europe and North America Focus

    20 Europe and North America Focus  Synthomer’s “Centre of Excellence” • Continuous improvement in SHE performance  Continue to take actions to address European low growth environment AND drive global business model • Low cost de‐bottleneck opportunities • Close control of fixed costs and capital e

  21. Slide 21: Asia and ROW Focus

    21 Asia and ROW Focus  Synthomer’s “Growth Engine” • CC strong in all territories, FP growing and HP very strong in APAC  Very dynamic environment with ongoing need for extra capacity and technology pull • Expansion opportunities in both NBR and dispersions  Build on European business model • Ong

  22. Slide 22: Outlook

    22 Outlook  Challenging environment in Europe likely to continue but lower input prices should be modest positive to offset demand concerns  Weakening of the Euro around year end will create a year‐on‐year translation impact  Confident of improved performance from nitrile on tighter supply demand

  23. Slide 23: Conclusion and Priorities

    23 Conclusion and Priorities  Safety, health and environmental (SHE) performance review  Full and detailed understanding of the existing business, assets and cost base  Optimise organisational structure  Clearly defined 5 year plan all business entities  Focus on growth opportunities • Low cost

  24. Slide 24: 2014 Preliminary Results

    2014 Preliminary Results 26th February 2015

  25. Slide 25: Balance sheet, Dividend and Capital Management policy

    25 Balance sheet, Dividend and Capital Management policy Balance sheet Investment opportunities Shareholder returns  Not to move structurally  Remain alert to acquisitions  Ordinary dividend moves to below 1x EBITDA 2.5x cover effective 2014 – New Geographies  Not to exceed 2x EBITDA for – New T

Synthomer — FY2014 Earnings Presentation on 6ix